Executive takeaways
- Discontinuing a device does not delete its UDI record: the data remains in the Global UDI Database (GUDID), but a flag and an end date signal that the product is no longer in commercial distribution.
- The Commercial Distribution End Date is a required data attribute: manufacturers must record when a product stops being distributed, even though units may remain in the supply chain or in customers' hands.
- End-of-life is a data event, not just a business event: labeling, packaging, PLM, ERP, and GUDID submissions all have to stay synchronized for the change to be compliant.
- Specialized expertise reduces risk: UDI lifecycle changes touch many systems at once, so a structured assessment-plan-execute approach helps device companies avoid gaps.
At some point in the future when a product is no longer distributed, the medical device company will need to put a commercial distribution end date into the Global UDI Database (GUDID). The product’s data will still reside in the database, but a flag will be set to let people know this product is no longer in distribution. The product may still be in the supply chain and people may still own it, but medical device companies are required to add a date of when the product is no longer being distributed.
What the GUDID Is and Why Discontinuation Still Matters
The Global Unique Device Identification Database is the U.S. Food and Drug Administration's publicly accessible reference for device identification information submitted under the Unique Device Identification (UDI) system established by the FDA's UDI Rule. Each device record is keyed to a Device Identifier (DI) — the mandatory, fixed portion of the UDI that identifies the labeler and the specific version or model of a device. GUDID stores the DI and a defined set of attributes about the device; it does not store the variable, production-specific portion of the UDI such as lot, serial, or expiration data that appears on the label and packaging.
Because GUDID is a registry of device identity, discontinuation is not handled by removing the record. Healthcare providers, patients, distributors, and other stakeholders may need to look up a device long after the manufacturer stops selling it — to confirm what they have, to support adverse event reporting, or to manage inventory already in the field. Preserving the record while clearly marking it as no longer distributed protects the traceability that the UDI system was built to provide.
The Commercial Distribution End Date Explained
The Commercial Distribution End Date is the data attribute that captures when a labeler stops distributing a device version or model. Setting it does not assert that every unit has left the supply chain — distributors may still hold stock and facilities may still own and use the device. It records the manufacturer's distribution decision so that the GUDID record accurately reflects the device's commercial status going forward.
This is why discontinuation is best understood as a lifecycle data event. A device's identity in GUDID moves through publication, ongoing maintenance of its attributes, and eventually an end-of-distribution state. Treating that final transition as a routine data update — rather than an afterthought once the product is already gone — keeps the public record trustworthy and keeps the manufacturer aligned with UDI recordkeeping expectations.
Why End-of-Life Changes Touch So Many Systems
Recording an end date sounds simple, but the data that flows into GUDID rarely originates in a single place. The Device Identifier and its attributes are typically governed across product lifecycle management (PLM) systems, enterprise resource planning (ERP) systems, labeling and artwork systems, and the interfaces that submit to GUDID itself. When a product is discontinued, those systems have to agree on the change, or the public record can drift out of step with internal reality.
The same data-integrity discipline that applies when a device is first introduced applies at end-of-life. Source data has to be accurate, the submission has to be complete, and the change has to be traceable. For organizations maturing how they manage regulated data across these systems, the principles of data integrity in life sciences are directly relevant: attributable, legible, contemporaneous, original, and accurate records do not stop mattering when a product reaches the end of its commercial life.
A Structured Approach to UDI Lifecycle Changes
Assess → Plan → Execute
- Assess: Review the products affected, the markets where they are sold, and the systems of record that hold their identification data. Confirm which records require a Commercial Distribution End Date and how end-of-life is currently triggered internally.
- Plan: Define an implementation strategy for the changes — including labels and packaging, the management of identification changes to each product, and the downstream impact on PLM, ERP, EPCIS, and packaging systems, as well as printing, vision inspection, and warehouse and inventory management systems.
- Execute: Make the changes, submit the updates through the GUDID interface, and verify that the public record and internal systems are consistent.
USDM Life Sciences will help you assess, plan and execute the changes and enhancements necessary to meet UDI regulations. Our team of UDI experts will assess your products, the markets where they are sold and determine an implementation strategy for the changes that need to be made. USDM's assessment methodology is extensive and includes the labels and packaging, the management of identification changes to each product, the changes to PLM, ERP, EPCIS and packaging systems, changes to printing, vision inspection and warehouse/inventory management systems and interfaces to the GUDID.
Validation and Governance Considerations
Because UDI data flows through computerized systems that produce regulated records, the systems and interfaces involved are commonly within the scope of computerized system validation. Organizations that have adopted the FDA's risk-based Computer Software Assurance (CSA) approach can apply that same critical-thinking model to UDI submission and labeling systems — focusing testing effort where the risk to record accuracy is highest. Where electronic records and electronic signatures are involved, 21 CFR Part 11 compliance expectations also apply to the systems that create, modify, and submit that data.
Discontinuation is also a good moment to confirm that ongoing governance keeps GUDID records accurate over time. As regulated cloud and SaaS platforms increasingly host this data, a continuous approach such as USDM Cloud Assurance helps ensure that vendor changes do not silently break the systems responsible for keeping device identity information correct.
How USDM Can Help
USDM's UDI experts work with device companies to make end-of-life changes accurate, traceable, and compliant — from assessing affected products and markets to coordinating the system and submission changes that keep the GUDID record true. If you are planning to discontinue a device, or want to mature how your organization handles UDI lifecycle changes, contact USDM Life Sciences to talk through an assessment and implementation strategy.
FAQ: Discontinued Devices and the GUDID
Does a discontinued device get removed from GUDID?
No. The device's Device Identifier record stays in GUDID so the device remains identifiable. The manufacturer sets a Commercial Distribution End Date and the record is flagged to indicate the product is no longer in distribution.
What is the Commercial Distribution End Date?
It is the data attribute that records when a labeler stops distributing a device version or model. It reflects the manufacturer's distribution decision — not a guarantee that every unit has left the supply chain or is no longer in use.
If units are still in the field, why mark the device as discontinued?
Because the end date describes distribution status, not physical inventory. Devices may still be owned and used after distribution ends, and keeping the record findable preserves traceability for providers, patients, and adverse event reporting.
Which internal systems are affected when we discontinue a device?
End-of-life changes can touch labels and packaging, PLM, ERP, EPCIS, packaging and printing systems, vision inspection, warehouse and inventory management, and the interfaces that submit to GUDID. These need to stay synchronized so the public record matches internal reality.
Is the GUDID submission system subject to validation?
The computerized systems and interfaces that create and submit UDI data generally fall within computerized system validation scope, and a risk-based CSA approach can be applied. Where electronic records and signatures are involved, 21 CFR Part 11 expectations also apply.